CROW Clinical is the Gold Coast device shop that shows up when a U.S. founder searches CROW Clinical, field clinical engineer Australia, or Australia medtech CRO and the protocol is procedure-heavy: electrophysiology, structural, imaging-guided, something that needs an engineer in the lab, not only a CRA in the monitoring plan. The site is live at crowclinical.com (retrieved 23 August 2026). It is small. It is device-tilted. It is not a Latin American first-in-human platform.
This is a practitioner comparison, not a smear. The public site names no trials and no sponsors. Competitive research compiled the same day places the firm in Gold Coast / Currumbin, Queensland (PO Box 35, Currumbin QLD 4223 is on the contact block), with LinkedIn also listing Brunswick, Victoria, and public employee counts in the 1–10 range. We will not invent a headcount, an email list, or a median start-up clock.
What CROW Clinical publishes
The homepage calls CROW “a full service and tailorable Clinical Research Organization servicing Australia and New Zealand” and then draws the line that matters: “We are the only CRO that offers a dedicated team of Field Clinical Engineers.” That is a company claim. Treat it as their differentiator, not as an audited market census. The firm “specialize[s] in high tech medical device start ups” and says it is “the experts for Med Tech and Biotech clinical trials.” Boutique pricing language: “premier … without the huge price tag,” “only pay for exactly what you need.”
Clinical operations copy cites ICH GCP, ISO 14155, and applicable regulations; QMS, eDC, and CTMS; study design, start-up, site selection, recruitment plans, project management, monitoring (including remote), data management, analytics, biostatistics, safety, medical writing, QA, auditing, and regulatory and reimbursement strategy support. Project management is framed as the central contact among ethics committees, regulators, vendors, and hospitals.
The field-clinical-engineer block is the product: case support and field support; “premier provider of Field Clinical Engineers in Aust and NZ”; “most trusted Clinical Engineers in the Southern Hemisphere” — company claims; live support “across different faculties of medicine”; corporate ambassadorship so engineers become an extension of the sponsor in the clinical environment. Telemedicine copy describes live streaming of camera images, fluoroscopy, EP recordings, hemodynamics, and device screens for virtual case presence.
CROW also offers trial sponsorship against Medsafe and Therapeutic Goods Administration responsibilities, and a commercialisation / real-world-evidence sentence about bringing products to market. Australia tax-incentive copy points readers to the ATO R&D tax-incentive page. It does not publish a rebate model, and we will not invent one for them.
Clinical areas listed: cardiology, denervation, diabetes, electrophysiology, imaging, implantables, medical devices, nanotechnology and biosensors, neurology and neurosurgery, neuromodulation, oncology, pain management, physician training, remote monitoring, renal / hepatobiliary / gastroenterology, vascular, wearables, and “state of art technology.”
Contact: inquiry form; careers to a published info@ address we will not reprint; postal address PO Box 35, Currumbin QLD 4223. Competitive mapping names Julie von Grum as CEO (also Managing Director, Clinical Engineers Australia / CEANZ). That name is not on the homepage fetch used for this article. Treat it as a public-map / directory identification, and confirm title in the RFP.
No named trial or sponsor appears on the public site.
Where a field-clinical-engineer CRO is the right tool
Hire CROW when the critical path is a complex procedure in an Australian or New Zealand lab and you want an engineer who can stand at the table, stream fluoro, and be the sponsor’s person in the room. That is a real gap on many “full-service CRO” org charts. It complements or substitutes the field-support benches at Mobius, AHS, and Ascend.
Do not hire CROW as the country strategy. ISO 14155 plus CTN/HREC plus a field engineer is an ANZ execution stack. It does not answer gross cash versus Latin America, and it does not create an eligible Australian R&D company. A one-to-ten-person shop can be the right prime for a single-site feasibility. It is a weak answer to “we need a nineteen-country option if ethics moves.”
Australia cash is not a 43.5% price cut
CROW’s site correctly points at the ATO incentive page. The math we will use is only the math already published:
- On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX). Sources: compare/australia, rebate article, Mobius pillar.
- A fully captured 43.5% refundable offset for groups under A$20 million aggregated turnover narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
- Capture needs an eligible Australian company. You fund the gross now. Cash returns after year-end lodgement.
- End-to-end start-up is broadly comparable once Australian site governance is included.
Local trial sponsorship (CROW’s TGA/Medsafe offer) is not the same fact as rebate eligibility. Do not collapse them on a board slide.
What bioaccess® is selling instead
bioaccess® is The First-in-Human CRO. Co-founded 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark (CEO). IMH ASSETS CORP. Miami headquarters, 1200 Brickell Ave, Suite 1950 #1034. Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires. FIH-only since 2010. 50+ pre-qualified sites across 19 countries; 50+ FIH/EFS studies supported; 50+ clients (about page). ISO 14155. English data packaged for 21 CFR 812.28 eligibility — FDA decides, case by case.
Colombia is current operations. As of 23 August 2026, bioaccess® still runs clinical trials in Colombia, keeps a local Colombian entity and office, manages INVIMA clocks in-country, and has 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. We do not tell sponsors to take new first-in-human work out of the country. See CRO in Colombia.
The product difference is structural. CROW is an ANZ boutique whose published edge is field clinical engineering. bioaccess® is a sixteen-year FIH house whose published edge is U.S. regulatory anchoring plus Latin American hospital volume and local entities. A U.S. founder who needs an engineer in a Gold Coast or Melbourne lab is buying the first product. A U.S. founder who needs first implants, an English 812.28 room, and a Miami counterpart on Eastern time is buying the second.
CROW Clinical vs bioaccess® — device FIH comparison
| Dimension | CROW Clinical | bioaccess® |
|---|---|---|
| Home geography | Gold Coast / Currumbin QLD (PO Box on site); ANZ coverage claimed | Miami HQ; local LATAM entities including Colombia |
| Public scale | Very small (1–10 on public directories / competitive map) | 50+ clients; 50+ FIH/EFS; 50+ sites (company about page) |
| Mix | High-tech device startups; biotech also claimed; field clinical engineers as differentiator | FIH/EFS devices (also biopharma / radiopharma FIH) |
| Named trials / sponsors | None on public site | Published case studies on bioaccessla.com |
| Leadership | Julie von Grum identified as CEO on competitive map; confirm on RFP — not on homepage fetch | Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill |
| Quality language | ICH GCP + ISO 14155; QMS / eDC / CTMS claimed | ISO 14155 → 21 CFR 812.28 (FDA decides) |
| Gross cash | Australia cost base; site points at ATO R&DTI; rebate only with an eligible AU entity | ~35–45% below Australia on gross, program experience |
| Colombia | Not a Colombia CRO | Still executing; local entity; INVIMA in-country |
How to keep CROW on the list without confusing the job
If the protocol is an ANZ procedure-heavy feasibility and you already have (or will form) the Australian entity the rebate requires, CROW belongs on the shortlist for field support — as prime if the rest of the TMF is real, as a subcontract if Mobius or AHS holds the CRO seat. Ask for a named or de-identified device case: class, implant versus energy versus EP, n, which engineer model (in-lab versus streamed), ISO 14155 monitoring plan, and English TMF.
If the protocol is a first implant that should start on Latin American cash and volume — including Colombia when that is the right INVIMA file — put bioaccess® in the prime column. Request a proposal at contact.
FAQ — CROW Clinical Australia
Is CROW Clinical a first-in-human device CRO?
The site is built for high-tech medical-device startups, implantables, EP, and ISO 14155. It does not publish a named FIH. FIH is implied by the customer type, not evidenced with a protocol name.
What is CROW’s differentiator?
Dedicated field clinical engineers and virtual case streaming (fluoro, EP, hemodynamics). “Only CRO” / “most trusted in the Southern Hemisphere” are their claims.
Who is the CEO?
Competitive research names Julie von Grum. Confirm on the RFP. The homepage fetch used for this article did not print an executive bio.
Is Australia cheaper after the R&D tax incentive?
Only with an eligible Australian company and a fully captured 43.5% offset, after you fund the gross. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience.
Does bioaccess® still run first-in-human trials in Colombia?
Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country. Colombia is not a retired geography.
Competitor facts from crowclinical.com, 23 August 2026, plus competitive map for CEO name, city, and employee-count band. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians.